Terconazole

Antifungal medication

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (±)-1-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-4-(p-chlorophenyl)piperazine | image = Terconazole_structure.svg | image2 = Terconazole_synthesis.svg }}

Terconazole is an antifungal medication primarily used to treat vaginal yeast infections. It belongs to the class of azole antifungals, which work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.

Medical uses

Terconazole is indicated for the treatment of vulvovaginal candidiasis, commonly known as a yeast infection. It is effective against infections caused by Candida albicans and other Candida species. Terconazole is available in various formulations, including vaginal creams and suppositories, which are applied directly to the affected area.

Mechanism of action

Structure of Terconazole

Terconazole functions by inhibiting the enzyme lanosterol 14α-demethylase, which is crucial in the biosynthesis of ergosterol. Ergosterol is a vital component of fungal cell membranes, and its inhibition leads to increased membrane permeability and ultimately cell death. This mechanism is similar to other azole antifungals, such as fluconazole and clotrimazole.

Pharmacokinetics

When administered intravaginally, terconazole is minimally absorbed into the systemic circulation, which reduces the risk of systemic side effects. The drug is metabolized in the liver and excreted primarily in the feces.

Side effects

Common side effects of terconazole include local irritation, burning, and itching at the site of application. Systemic side effects are rare due to the low absorption of the drug. However, patients should be advised to discontinue use and seek medical attention if they experience severe reactions.

Synthesis

Synthesis of Terconazole

The synthesis of terconazole involves the formation of a triazole ring, which is a characteristic feature of azole antifungals. The process includes the reaction of a dichlorophenyl compound with a triazole derivative, followed by the formation of a dioxolane ring. This synthetic pathway is designed to produce a compound with high antifungal activity and minimal side effects.

Related pages

• Antifungal medication
• Vaginal yeast infection
• Azole antifungals